Multimodal and data-driven assessment of myeloid neoplasms refines classification across disease states Journal Article


Authors: Lachowiez, C. A.; Asimomitis, G.; Bernard, E.; Devlin, S. M.; Tazi, Y.; Creignou, M.; Germing, U.; Gattermann, N.; Gilkes, A.; Thomas, I.; Bullinger, L.; Döhner, K.; Malcovati, L.; Othman, J.; Dillon, R.; Eisfeld, A. K.; Nicolet, D.; Issa, G. C.; Daver, N.; Kadia, T. M.; Dinardo, C. D.; Ravandi, F.; Garcia-Manero, G.; Montalban-Bravo, G.; Russell, N.; Cazzola, M.; Döhner, H.; Huntly, B. J. P.; Hasserjian, R. P.; Hellström-Lindberg, E.; Papaemmanuil, E.; Loghavi, S.
Article Title: Multimodal and data-driven assessment of myeloid neoplasms refines classification across disease states
Abstract: <p>The World Health Organization fifth edition and International Consensus Classification for myeloid neoplasms both incorporate empirical numerical thresholds to morphologic and molecular features defining certain disease entities. However, the clinical implications of these thresholds remain unclear. We analyzed a large cohort (N = 6,976) of patients with myeloid neoplasms to evaluate the impact of proposed yet different numerical thresholds for variant allele frequency of genetic mutations or hematologic parameters set forth by the World Health Organization fifth edition and International Consensus Classification for classification of SF3B1-mutated myelodysplastic neoplasms, NPM1-mutated acute myeloid leukemia (AML), and oligomonocytic chronic myelomonocytic leukemia. Our analysis demonstrated that the clonal burden of SF3B1 mutation in myelodysplastic neoplasms informs classification and prognosis. Our findings support the notion that NPM1 mutation should be AML-defining regardless of blast percentage and highlight the adverse prognostic impact of the cumulative number of myelodysplasia-related mutations in NPM1-mutated AML. Finally, we provide evidence that integrating specific molecular signatures could improve the accuracy of oligomonocytic chronic myelomonocytic leukemia classification.Significance: Using comprehensive clinical and molecular profiling, this study provides a data-driven approach for evaluating numerical thresholds of variant allele frequency or hematologic parameters (i.e., blast percentage and absolute monocyte count) included in current classification schemas across a spectrum of myeloid malignancies, enabling refinement of disease classification and prognostication.</p>
Keywords: leukemia; impact; aml; mds; npm1 mutations
Journal Title: Blood Cancer Discovery
Volume: 6
Issue: 5
ISSN: 2643-3230
Publisher: American Association for Cancer Research  
Date Published: 2025-09-01
Start Page: 425
End Page: 436
Language: English
ACCESSION: WOS:001564194800001
DOI: 10.1158/2643-3230.Bcd-25-0047
PROVIDER: wos
PMCID: PMC12294350
PUBMED: 40608896
Notes: Corresponding MSK author is Elli Papaemmanuil -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sean McCarthy Devlin
    617 Devlin
  2. Yanis Tazi
    8 Tazi